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Summary: Over the past several years, there has been an increasing
research effort focused on inhibition of protein–protein interactions
(PPIs) to develop novel therapeutic approaches for cancer, including
hematologic malignancies. These efforts have led to development of
small molecule inhibitors of PPIs, some of which already advanced to
the stage of clinical trials while others are at different stages of preclin-
ical optimization, emphasizing PPIs as an emerging and attractive class
of drug targets. Here, we review several examples of recently devel-
oped inhibitors of PPIs highly relevant to hematologic cancers. We
address the existing skepticism about feasibility of targeting PPIs and
emphasize potential therapeutic benefit from blocking PPIs in hemato-
logic malignancies. We then use these examples to discuss the
approaches for successful identification of PPI inhibitors and provide
analysis of the protein–protein interfaces, with the goal to address
‘druggability’ of new PPIs relevant to hematology. We discuss lessons
learned to improve the success of targeting new PPIs and evaluate pros-
pects and limits of the research in this field. We conclude that not all
PPIs are equally tractable for blocking by small molecules, and detailed
analysis of PPI interfaces is critical for selection of those with the high-
est chance of success. Together, our analysis uncovers patterns that
should help to advance drug discovery in hematologic malignancies by
successful targeting of new PPIs.
Keywords: Protein–protein interactions, drug discovery, hematologic malignancies
Introduction
Limited success and toxicity of conventional chemotherapy
in the treatment of hematologic malignancies emphasize the
need for development of targeted therapies, which are
expected to be more effective and less toxic than chemo-
therapy agents. Targeted agents, exemplified by the number
of monoclonal antibodies and small molecule inhibitors cur-
rently in clinical use or in clinical trials, have a history of
success in the treatment of hematologic malignancies, either
as single agents or in combination with chemotherapy
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agents (1–3). The approval of imatinib (Gleevec) in 2001
for the treatment of chronic myeloid leukemia (CML) and
its high success rate (approximately 90% five-year survival)
support the extensive efforts to develop novel molecularly
targeted therapies for hematologic cancers (4). The majority
of small molecule targeted agents developed for hematologic
malignancies block activity of protein kinases, including
FLT3, Aurora kinase, JAK1/2, Akt, and mTOR (2, 3). Addi-
tional examples include proteasome inhibitors (5) and epi-
genetic/demethylating agents, such as inhibitors of histone
deacetylases and DNA or histone methyltransferases (HMTs)
(2, 3, 6–8). These agents, however, are still under active
investigation at different stages of clinical trials to validate
their clinical applicability (1–3).
Studies on the mechanistic basis of tumorigenesis allow
understanding how genetic and epigenetic modifications
lead to different subtypes of cancers (9–11). In many hema-
tologic cancers, genetic profiles are well defined (12). The
ability to develop new effective drugs relies on understand-
ing biological mechanisms connecting specific genetic
abnormality with disease progression. Likewise, analysis of
the molecular basis of tumorigenesis reveals proteins that
play a critical role in oncogenesis and provides novel molec-
ular targets for therapeutic intervention. Among molecular
targets critical in pathogenesis of different types of cancer,
the protein–protein interactions (PPIs) play a very important
role (13, 14). Under normal physiological conditions PPIs
hold together multi-protein complexes in cells to control
essentially all cellular processes (15, 16). Therefore, it is not
surprising that many PPIs have been recognized as an
emerging class of molecular targets in different diseases,
including cancer (13, 16, 17). PPIs were, however, consid-
ered as either very challenging or even ‘undruggable’ tar-
gets. The main challenges in targeting PPIs were linked to
the flexibility, large size, and complex topology of PPI inter-
faces. These features, together with poor compatibility of
PPI interfaces with small molecules available in screening
libraries limited the applicability of classical drug screening
approaches for identification of PPI inhibitors (18). Despite
these challenges and limitations, a number of PPIs were suc-
cessfully explored for drug discovery purposes, both in aca-
demia and industry, leading to small molecules that have
already entered clinical trials in oncology (18–20) (Table 1).
These successful examples have changed the general concept
of targeting PPIs, which are no longer considered uniformly
‘undruggable’.
The limited success of conventional chemotherapy cur-
rently used for treatments in hematologic cancers clearly sup-
ports the need for development of new treatment options
(1–3, 21). Improved understanding of PPI networks and suc-
cess in targeting PPIs by small molecules (19, 22) has
encouraged a number of research groups to pursue similar
studies in hematologic cancers. In this review, we discuss
examples of recently developed small molecule inhibitors of
PPIs that are highly relevant to hematologic cancers (Fig. 1),
to address the existing skepticism about feasibility of target-
ing PPIs and emphasize the potential therapeutic benefit from
blocking PPIs in hematology. These examples are particularly
instructive, as they represent different types of structurally
characterized PPIs, providing the opportunity to analyze
which PPIs are most tractable as drug targets. We then use
these examples to discuss the approaches for successful iden-
tification of PPI inhibitors, deliberate on the role of structural
biology in this process, and propose when lead optimization
should convert into a drug discovery project. This analysis
will assess lessons learned to improve the success of targeting
new protein–protein interfaces and will evaluate prospects
and limits of the research in this field, where inhibitors are
still difficult to identify. Together, our analysis uncovers
patterns that should help to advance drug discovery in hema-
tologic malignancies by successful targeting of new protein–
protein interfaces.
Table 1. Small molecule inhibitors of protein–protein interactions currently in clinical trials for hematologic malignancies
Drug candidate Target protein Indication Status Reference
RO5045337 MDM2-p53 Hematologic neoplasms (leukemia) Phase 1 (194)
PRI-724 CBP/beta-catenin AML, CML Phase 1/2 (195)
TL32711 SMAC mimetic AML, ALL, MDS Phase 1/2 (196)
LCL161 SMAC mimetic Multiple myeloma Phase 2 (197)
ABT-263 Bcl-2-BH3 Hematological cancers (lymphoma, leukemia) Phase 1/2 (167, 198)
GX15-070 Bcl-2 family—BH3 Hematological cancers (lymphoma, leukemia) Phase 1/2 (199)
GSK525762 BET bromodomains Hematologic Malignancies Phase 1 (88)
OTX015 BET bromodomains Hematologic Malignancies Phase 1 NCT01713582*
CPI-0610 BET bromodomains Lymphoma Phase 1 NCT01949883*
*Clinical trial identifier.
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This review article starts with the discussion on how attrac-
tive PPIs are as drug targets, followed by addressing major
challenges in targeting protein–protein interfaces with small
molecules. We then provide several successful examples of
small molecules blocking PPIs relevant to hematology to dem-
onstrate that PPIs are tractable drug targets. This is followed
by lessons learned from blocking PPIs, including a description
of methods and approaches used for identification of PPI
inhibitors, the importance of crystal structures, discussion on
druggability of PPI interfaces, as well as the role of academic
laboratories in this process. This article concludes with a dis-
cussion on what has changed over time in targeting PPIs,
which questions still remain to be answered, and what is the
future of targeting PPIs for development of novel therapeutics.
Are PPIs attractive drug targets?
Targeting PPIs with small molecules is considered much
more challenging than inhibiting classical drug targets such
as enzymes, receptors, or ion channels (23–25). Therefore,
the key questions are whether such efforts will pay off and
whether inhibitors of PPIs will offer significant benefits. PPIs
play critical roles in many biological processes, under both
physiological and pathological conditions. It has been esti-
mated that 130 000 to 650 000 PPIs may occur in human
cells (26, 27), and therefore the number of potential PPIs as
drug targets is large and significantly exceeds the druggable
human kinome (28). Targeting PPIs also provides an attrac-
tive opportunity to directly target proteins that drive disease
development. For example, oncogenic activity of mixed
A B
C
D
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Fig. 1. Chemical structures and inhibitory activity of protein–protein interaction (PPI) inhibitors developed for hematology-related
protein targets. (A) ABT-263 targeting Bcl-2 family of proteins. (B) Small molecule inhibitors of the menin–MLL interaction: MI-2-2 and MIV-
6R. (C) Inhibitors of WDR5–MLL interaction: small molecule WDR5-0103 and peptidomimetic MM-401. (D) Small molecule inhibitor of CBFb–
Runx1 interaction: cpd 14. (E) Inhibitors of BET bromodomains: JQ1 and I-BET151. (F) Small molecule inhibitor of BCL6: 79-6.
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lineage leukemia (MLL) fusion proteins in leukemia is
dependent of their interactions with menin (29). Hence,
direct inhibition of the menin-MLL PPI with small molecules
may represent a more attractive strategy to reverse onco-
genic activity of MLL fusion proteins than targeting down-
stream signaling pathways.
As discussed previously, targeting PPIs may offer advanta-
ges over enzyme inhibition (25). Development of selective
inhibitors to block enzymatic activity of kinases (e.g. ATP
mimetics) or methyltransferases (e.g. S-adenosylmethionine
mimetics) represents a challenge due to high conservation of
binding sites across family members. Since PPI interfaces vary
significantly between different protein complexes, inhibitors
targeting PPIs may be more selective than kinase inhibitors
competing for relatively conserved ATP-binding sites. Fur-
thermore, activity of kinases is regulated via multiple PPIs,
and therefore targeting these interactions may allow achieve-
ment of higher level of selectivity or different biological
responses as compared to blocking kinase activity by the ATP
competitive inhibitors (25). Availability of PPI inhibitors
might allow for combinatorial treatment with kinase inhibi-
tors to more efficiently block signaling pathways.
One of the major concerns about targeted therapy is
development of resistance mechanism and loss of drug effi-
cacy, which may arise from mutations in the target protein
leading to the loss of drug binding. For example, mutations
in the catalytic domain of BCR-ABL lead to resistance to
imatinib (Gleevec) in CML patients (30, 31). Furthermore,
the C481S mutation in the catalytic domain of the Bruton’s
tyrosine kinase (BTK) was recently reported to confer resis-
tance to ibrutinib, an inhibitor of BTK that has been
approved in 2014 for the treatment of CLL (32). Mutations
of other mechanisms, such as amplification of the receptor
kinase or activation of an independent signaling pathway,
may result in resistance to the kinase inhibitor drugs (33).
In contrast, there is an attractive opportunity that drugs tar-
geting PPIs will be less prone to the resistance mechanism,
particularly when resistance is due to mutations in the pro-
tein target. Residues at the PPI interfaces are highly evolu-
tionarily conserved and they evolve slower than residues at
non-binding surfaces (34, 35). Furthermore, the PPI inter-
faces have relatively tight packing (36), and mutations pre-
dominantly weaken PPIs (37). Therefore, spontaneous
mutations at PPI interfaces would have high likelihood of
disrupting or weakening the interactions between natural
protein partners. Obviously, the same mutations may impair
small molecule binding. However, small molecules typically
utilize significantly smaller binding interfaces (Figs 2 and 3),
and therefore there is a higher probability that mutations at
PPI interfaces will disrupt or weaken PPIs rather than small
molecule binding to the target protein. This has been exem-
plified by the recent studies by Jung et al., in which muta-
tions in BRD4 bromodomain were evaluated for their impact
on interactions with either a natural binding partner, an acety-
lated histone 4 (ac-H4) derived peptide, or a potent small
molecule inhibitor JQ1 (38). The majority of mutations
Fig. 2. Binding modes of selected protein–protein interaction (PPI) inhibitors to protein targets. JQ1:Brd4 (PDB code 3MXF), ABT-263:Bcl-2
(4LVT), MM-104:WDR5 (4GM9), 79-6:BCL6 (3LBZ), MI-2-2-menin (4GQ4), and cpd 10-CBFb (43), demonstrating how small molecule
inhibitors bind to the surface pockets at PPI interfaces. Small molecule inhibitors are shown in stick representation with carbons in green, oxygens
in red, nitrogens in blue, sulfur in yellow, and fluorines in cyan. Protein is shown in surface representation with white carbons, blue nitrogen,
red oxygen, and yellow sulfur atoms.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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decreased binding of both, ac-H4 peptide and JQ1, although
binding of ac-H4 was impaired more pronouncedly. There
was only one mutation (P82A), which resulted in signifi-
cantly stronger reduction in JQ1 binding to BRD4 as com-
pared to ac-H4. This example demonstrates that drug
resistant mutations in BRD4 are possible; however, a great
majority of mutations would also impair binding of the pro-
tein partner.
Several agents targeting PPIs are currently being evaluated
in clinical trials in hematological cancers (Table 1), and to
our knowledge, no naturally occurring mutations that would
impair drug binding to the target protein have been
described. These compounds, however, are still at relatively
early stages of clinical evaluation (Table 1), and the hypothe-
sis that targeting PPIs would lead to fewer resistance muta-
tions remains to be robustly tested. Incoming data from
clinical trials will address this important issue and provide a
better understanding of resistance mechanism to PPI inhibi-
tors.
Challenges in targeting protein–protein interactions
Successes and failures in targeting PPIs allow better
understanding of the features at PPI interfaces that limit
development of small molecule inhibitors. The main chal-
lenges in targeting PPIs arise from the complexity and flexi-
bility of PPI interfaces and the relatively poor compatibility
of binding pockets at the interfaces with compounds cur-
rently available in screening libraries.
Complexity of PPI interfaces
PPI interfaces are complex and vary significantly between
different types of protein–protein complexes. Three different
types of protein–protein interfaces can be distinguished:
(i) globular domain–peptide interactions (Fig. 4A and B);
(ii) interactions involving folded globular domains (Fig. 4C);
and (iii) interactions of intrinsically unstructured proteins.
The majority of the best characterized PPIs fall into the class
of complexes involving globular domains. These interactions
usually have non-contiguous nature and involve relatively
flat and large surface areas (1200 to 3000 A2) (39, 40).
They often lack surface pockets, which make them difficult
for disruption by orthosteric inhibitors that bind to the PPI
interfaces. Development of allosteric inhibitors might repre-
sent an alternative approach to target such PPIs (41–43).
The feasibility of developing allosteric inhibitors is, how-
ever, difficult to predict until such molecules are identified
Fig. 3. Comparison of protein-small molecule contacts with protein–protein (or protein–peptide) interaction interfaces. Target protein is
shown in surface representation (gray), protein (or peptide) binding partner is shown in semi-transparent surface (magenta) and inhibitors are
shown as sticks (cyan/blue). Blue color corresponds to the region of the ligand molecule that overlaps with binding of the protein (peptide)
partner, while cyan color corresponds to the ligand portion that does not overlap with binding of the protein (peptide) partner. PDB codes for
PPI complexes are as follows: Brd4-acH4 (3UVW), WDR5-MLL2 (3UVK), BCL6-SMRT (1R2B), Bcl-2-BAX (2XA0); menin-MLL (3U88); CBFb-
Runx1 (1H9D). The PDB structures for protein-inhibitor complexes are the same as shown in Fig. 2. PPI, protein–protein interaction.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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in screens and validated for binding to the allosteric sites on
proteins using structural biology or mutagenesis studies.
More attractive opportunities for small molecule develop-
ment represent PPIs, where globular domain engages a
peptide-like fragment of a protein partner. These protein–
peptide type interactions account for up to 40% of all PPIs
(44). The average surface areas at the protein–peptide inter-
faces are much smaller, and reach about 500 A2 (45).
Importantly, these interfaces frequently contain well-defined
binding pockets and have been recognized as more suscepti-
ble to targeting by small molecule inhibitors.
The most complex and least understood are PPIs involving
intrinsically disordered proteins (IDPs) (46), which remain
unfolded in the absence of protein partners and fold into a
globular structure upon binding (47, 48). Formation of IDP
complexes typically results in large contact areas and com-
plex PPI interfaces. IDPs have been identified as hubs in the
PPI networks (49), and are potentially valuable drug targets.
However, whether such interactions can be disrupted by
small molecules still remains to be determined.
Despite large size and complexity of PPI interfaces, it has
been demonstrated that relatively few residues at the inter-
faces are essential for high affinity interactions (50, 51).
These residues contribute to the majority of binding energy
and are called ‘hot spots’ (50–53). ‘Hot spot’ residues
constitute less than half of the binding surface and are usu-
ally found in the center of the contact interface (54). The
‘hot spot’ amino acids are frequently conserved across
different protein families and became buried upon complex
formation (35). Hydrophobic residues, such as tryptophan,
tyrosine, phenylalanine, methionine, and arginine, are the
most frequent ‘hot spots’ identified at PPI interfaces (51,
52). Identification of ‘hot spot’ residues can be achieved via
alanine scanning mutagenesis (50). Localization of ‘hot
spots’ at PPI interface is valuable to guide ligand develop-
ment, and it has been found that PPI ‘hot spots’ largely cor-
relate with the sites where small molecules bind (55).
Pockets at PPI interfaces are not compatible to bind
small molecules
Structural analysis of protein complexes demonstrates that
despite a common belief about the lack of pockets at PPI
interfaces, such pockets are indeed frequently present. How-
ever, the topology of these pockets differs from those found
in classical drug targets, such as enzymes, ion channels and
receptors (56–58). It has been noted that high affinity PPIs
involving fairly localized contacts are most amenable to inhi-
bition, while weaker interactions with large contact areas are
much more difficult to disrupt using small molecules (59).
Pockets at PPI interfaces are also fairly hydrophobic and
A
B
C
Fig. 4. Types of ‘druggable’ protein–protein interaction (PPI) interfaces. (A) Short peptide—domain interaction. (B) Long peptide—domain
interaction. (C) Domain–domain interaction. Target proteins are shown in surface representation (gray), and binding partners are shown in
ribbon and stick representations (carbon atoms in green, oxygen in red, nitrogen in blue, sulfur in yellow). Accessible solvent area (ASA) buried
in complex formation has been calculated with 2P2I inspector software (200) using the same PDB structures as in Fig. 3.
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enriched in aromatic residues (52, 60). These features make
PPIs not fully compatible with physicochemical properties of
known small molecule drugs (61).
Flexibility and dynamics of residues at PPI interfaces
Availability of protein structures is critically important for
development of PPI inhibitors. However, PPI interfaces are
frequently dynamic, and unbound proteins may exist in
multiple conformational states (62). In fact, flexibility at PPI
interfaces is an intrinsic property of many proteins and
might be functionally important. For example, conforma-
tional plasticity in the Bcl-2 family of proteins allows for
binding to multiple distinct BH3-only proteins (63).
Flexibility and dynamics at PPI interfaces represents a
challenge for designing small molecule inhibitors, particu-
larly when structure-based drug design methods are applied.
On the other hand, dynamics of PPI interfaces may create
opportunities for inhibitor discovery. For example, pockets
might not be present in the crystal structures of uncom-
plexed proteins, while large pockets suitable to bind small
molecules may exist in solution (64). Small molecules are
also capable of causing conformational changes upon bind-
ing to the orthosteric or allosteric sites and induce formation
of new pockets (65).
Structural information on protein–protein complexes is
typically obtained from analysis of the crystal structures,
which provide a static picture of PPI interfaces. Protein con-
formation in the crystal state represents a selected low energy
conformation, while multiple conformations may exist in
solution. In addition, crystal structures may be distorted due
to crystal packing forces. NMR spectroscopy provides a valu-
able alternative method for protein structure determination in
solution. However, structural studies on protein-ligand com-
plexes by NMR still represent a challenge (66). Another
approach to account for conformational dynamics of proteins
is molecular dynamics (MD). Multiple snapshots of protein
conformations can be taken from MD simulations to be subse-
quently used as a basis for ligand docking (67–69). Overall,
flexibility at PPI interfaces complicates structure-based design
of small molecule inhibitors but simultaneously offers an
attractive opportunity for identification of new unexpected
binding sites and allows for targeting of challenging PPIs.
PPIs are tractable drug targets in hematologic
malignancies: case studies
Successful identification and development of small molecules
to block PPIs in cancer have been demonstrated for a number
of protein targets (19, 22, 23, 70). These examples include
inhibitors of the anti-apoptotic Bcl-2 family of proteins
implicated in different hematologic malignancies (71–74),
with selected compounds (e.g. ABT-263) (Fig. 1A) currently
in clinical trials for lymphoid malignancies (22, 72, 73).
Inhibition of the MDM2–p53 interaction with small mole-
cules represents another example of PPIs where very potent
drug-like molecules were developed (75, 76), and are being
evaluated in clinic for different types of cancers, including
AML and lymphoma (22, 77). More recently, there has been
extensive progress in development of small molecule inhibi-
tors targeting other PPIs implicated in hematologic cancers.
Successful examples include development of inhibitors target-
ing PPIs critical to oncogenic activity of MLL fusion proteins
in MLL rearranged leukemias (78–82), compounds blocking
the Core Binding Factor beta (CBFb) in acute leukemia (43,
83), and inhibitors of the BET family of bromodomains,
which demonstrated activity in AML and multiple myeloma
(84–86) (Fig. 1B–E). Furthermore, small molecules targeting
the protein–protein interface on Bcl-6 have also been devel-
oped as a potential therapeutic strategy for B-cell lymphoma
(87) (Fig. 1F). Many of these PPI inhibitors have been devel-
oped within the last 5 years, primarily in academic laborato-
ries, and are currently at different stages of preclinical
optimization, with BET bromodomain inhibitors already
advanced to clinical trials (88) (Table 1), as discussed below
in detail. These examples represent different types of PPIs and
are accompanied by detailed structural characterization of the
protein-ligand complexes, providing the opportunity to ana-
lyze which PPIs are most tractable as drug targets to find
common features for improving the success of targeting new
protein–protein interfaces relevant to human diseases.
Small molecule inhibitors of the menin–MLL interaction
Chromosomal translocations that affect the MLL (mixed lineage
leukemia) gene (in this review MLL uniformly refers to the
MLL1 gene) occur in about 5–10% of acute leukemias in
adults (89) and approximately 70% of acute leukemias in
infants (90). Translocations of MLL result in expression of
chimeric MLL fusion proteins, which retain the N-terminal
MLL fragment of approximately 1400 amino acids fused
with one out of over 60 fusion partners (91–94). Patients
with MLL leukemias are refractory to currently available
treatments (91, 95, 96), emphasizing the urgent need for
development of novel therapies. Indeed, different novel
therapeutic strategies are being explored, including small
molecule inhibition of the Dot1L HMTs (8, 97), Flt3 recep-
tor tyrosine kinase (98), GSK3 kinase (99), and cyclin
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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dependent kinase 6 (CDK6) (100), all of which rely on
inhibition of the enzymatic activity of proteins implicated in
pathogenesis of MLL leukemia.
The chromosomal rearrangements of the MLL gene affect
only one allele, while the second allele almost always remains
intact (101). MLL is a member of the MLL family of HMTs,
which catalyzes methylation of histone H3 on K4 through
the SET domain located at the C-terminus of MLL (102,
103). Thiel et al. (104) demonstrated that HMT activity of
the wildtype MLL is required to cooperate with MLL-AF9 in
leukemogenic transformation. MLL requires other proteins,
including WDR5, ASH2L, and RbBP5, to assemble a catalyti-
cally active complex (105), and the interaction between MLL
and WDR5 is critical for the integrity of this complex and for
its methyltransferase activity, representing a potential drug
target in MLL leukemias (see below) (105, 106).
Our own efforts to block oncogenic MLL fusion proteins
have been focused on applying a different approach, specifi-
cally on inhibiting the PPI between MLL fusion proteins and
menin, which has been well validated to play a critical role
in development and progression of MLL leukemias (29,
107, 108). Menin is a highly specific binding partner of
MLL fusion proteins, and this interaction is essential for
their leukemogenic activity (29). Therefore, disruption of
the PPI between menin and MLL fusion proteins represents
a very attractive therapeutic strategy to develop new targeted
drugs for MLL leukemias.
Menin interacts with two N-terminal fragments of MLL,
namely MBM1 and MBM2 (menin-binding motif 1 and 2),
with MBM1 (MLL4-15) representing high affinity binding
motif that binds to menin with Kd of 56 nM (109). Studies
from our group (79, 110) and by others (111) resulted in
determination of the crystal structure of menin and the
menin-MLL complex, demonstrating that MLL binds to the
large central cavity on menin (Fig. 4B). Detailed analysis of
the crystal structure and alanine scanning mutagenesis
revealed that three hydrophobic residues of MLL, F9, P10,
and P13 that bind to well-defined hydrophobic pockets on
menin, contribute most to the binding affinity (79, 109,
111) (Fig. 5A).
A
C D
B
Fig. 5. Comparison of binding modes of natural protein partners and small molecule inhibitors of protein–protein interactions (PPIs).
Details of the interaction of MLL derived peptide (A) and MI-2-2 (B) with menin, demonstrating that MI-2-2 occupies the same region of the
binding site and closely mimics key interactions of MLL (in particular residues F9 and P13) with menin (PDB codes: 4GQ6 and 4GQ4,
respectively). Comparison of the binding mode of acetylated H4 peptide (C) and JQ1 (D) to Brd4 (PDB codes: 3UVW and 3MXF, respectively).
Protein residues, peptides and small molecules are shown in stick representations, with carbon atoms in gray (proteins) or green (peptides and
small molecules). Color coding for other heavy atoms remains the same for all complexes: oxygens in red, nitrogens in blue, sulfur in yellow,
and fluorines in cyan. Dashed lines correspond to hydrogen bonds.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
286 Immunological Reviews 263/2015
Cierpicki & Grembecka  Targeting protein–protein interactions in hematology
We reported development of two classes of small mole-
cule inhibitors of the menin–MLL interaction (78–80), in
addition to recently reported peptidomimetics (112). By
applying high throughput screening (HTS) of 49 000 small
molecules, we identified a thienopyrimidine class of menin-
MLL inhibitors, with the most potent being MI-1, which
directly binds to menin and inhibits the menin–MLL interac-
tion with IC50 of 1.9 lM (78). Our initial medicinal chem-
istry efforts performed in the absence of structural
information on the menin-ligand complexes resulted in MI-
2 (IC50 = 0.46 lM). Further optimization of this class of
menin-MLL inhibitors was possible when MI-2 was cocrys-
talized with menin (79). Using structure-based design we
developed MI-2-2 with approximately 10-fold increased in
vitro inhibitory activity (IC50 = 46 nM, Kd = 22 nM) (79)
(Figs 1B and 5B). Interestingly, MI-2-2 has a similar binding
affinity to menin as the 12 amino acid MBM1 MLL derived
peptide, despite almost fivefold smaller molecular weight.
Strong potency of MI-2-2 is attributed to the fact that it
binds to the MLL binding site on menin (Figs 2 and 3) and
closely mimics key interactions of MLL with menin, in par-
ticular the interactions involving F9 and P13 residues of
MLL (79) (Fig. 5A and B). This demonstrates that small mole-
cule inhibitors of PPIs can achieve strong potency by mim-
icking the interactions identified for the natural protein
partner. When tested in MLL leukemia cells, both MI-2 and
MI-2-2 selectively blocked proliferation, induced apoptosis
and differentiation and reversed the MLL fusion protein
mediated leukemic transformation by downregulating MLL
fusion protein target genes, including Hoxa9 and Meis1 (78,
79). Furthermore, both compounds also depleted the MLL-
AF9 complex from the Hoxa9 locus and reduced H3K4me3
and H3K79me2 methylation level (78, authors’ unpublished
data), validating their specific mechanism of action. The cel-
lular effects in MLL leukemia cells are more pronounced for
MI-2-2, correlating with its stronger in vitro inhibition of the
menin–MLL interaction (79).
We have also reported another class of menin-MLL inhibi-
tors, the methyl-piperidine compounds, identified by HTS
of approximately 280 000 compounds at the NIH MLPCN
(Molecular Libraries Probe Production Centers Network,
https://mli.nih.gov/mli) (80). The initial HTS hit, MIV-1,
showed only modest inhibitory activity (IC50 = 12 lM) and
was further optimized using structure-based design approach
to develop MIV-6R (IC50 = 56 nM, Kd = 85 nM) (80)
(Fig. 1B). Interestingly, the methyl-piperidine menin-MLL
inhibitors more closely mimic the MLL binding mode to
menin than thienopyrimidine compounds, as they occupy
all three pockets on menin required for high affinity bind-
ing of MLL (F9, P10, P13). MIV-6R demonstrated specific
growth arrest and differentiation in MLL leukemia cells,
accompanied by downregulation of MLL fusion protein tar-
get genes, demonstrating a specific mechanism of action
(80). Overall, the two classes of small molecule inhibitors
of the menin–MLL interaction described here validate that
pharmacologic inhibition of this PPI is feasible and can
reverse the MLL fusion protein mediated oncogenic transfor-
mation. These compounds are currently under development
in our laboratory to further improve their potency and other
drug-like properties to develop compounds for therapeutic
applications.
The MLL derived macrocyclic peptidomimetics were
reported recently as potent in vitro inhibitors of the menin–
MLL interaction (Ki = 4.7 nM for MCP-1) (112). However,
cellular activity of these compounds was not reported, sug-
gesting that optimization of their drug-like properties is
likely required to identify therapeutically useful com-
pounds. Nevertheless, the success with developing different
classes of small molecules and peptidomimetics demon-
strates that the menin–MLL interaction represents a drugga-
ble target for therapeutic intervention. Because this PPI is
essential for the MLL fusion mediated leukemogenesis, we
believe that disruption of this interaction with small mole-
cules will directly inactivate MLL fusion proteins and will
represent an optimal approach for therapeutic intervention
in MLL leukemias.
Inhibitors of the WDR5–MLL interaction
The WDR5–MLL interaction represents another example of
PPIs relevant to the MLL fusion protein oncogenic transfor-
mation (see above) (81) and an attractive molecular target
for small molecule intervention in MLL rearranged leuke-
mias. WDR5 binds to the catalytic subunit of MLL with
nanomolar affinity (Kd = 120 nM) using a 12 amino acid
fragment called ‘WIN motif’ (113). Further studies identified
a three amino acid fragment of MLL, Ac-ARA-NH2, which
binds to WDR5 with the same potency as the catalytic sub-
unit of MLL (114). The crystal structure of the MLL derived
peptide in complex with WDR5 revealed that the Arg3765
side chain of MLL binds to a deep pocket on WDR5 and is
involved in an extensive network of hydrogen bonds (113),
providing the structural basis for targeting this PPI.
Two groups reported development of small molecule and
peptidomimetic inhibitors of the WDR5–MLL interaction
(81, 82, 115, 116). Small molecule inhibitors of WDR5–
MLL interactions were identified by HTS of 16 000 diverse
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small molecules, resulting in WDR5-0101 (82). Exploration
of commercially available analogs yielded WDR5-0103, with
about 10-fold higher potency than the parent compound
(Kd = 0.45 lM, IC50 = 3 lM) (82) (Fig. 1C). Structural
studies of WDR5 with a close analog of WDR5-0103
showed that the piperazine moiety of the ligand fits into the
pocket on WDR5 that accommodates the arginine residue
from the ‘WIN motif’ (82). Importantly, WDR5-0103 was
shown to inhibit catalytic activity of MLL, albeit with mod-
erate affinity (IC50 = 83 lM), by antagonizing the interac-
tion of WDR5 with MLL. More potent analogs, however,
are required to fully assess the effect of small molecule
inhibitors of WDR5 in cancer cells.
A potent class of peptidomimetics has been developed to
block the WDR5-MLL PPI (81, 116). The linear peptidomi-
metics, including MM-101 and MI-102 with very potent
binding affinity to WDR5 (Ki < 1 nM, IC50 < 3 nM), were
developed first (116) and used for structure-based design of
cyclic compound MM-401 (81) (Fig. 1C). The MM-401
maintained high binding affinity to WDR5 (Kd < 1 nM)
and very strong inhibition of the WDR5–MLL interaction
(IC50 = 0.9 nM) due to a restricted conformation and addi-
tional hydrophobic contacts over MM-102, as validated by
the crystal structure of the complex (81) (Figs 2–3). MM-
401 was effective and selective in inhibiting the MLL1 HMT
activity in vitro, although with modest affinity
(IC50 = 0.32 lM) (81). Importantly, MM-401 was shown
to specifically inhibit the MLL-dependent H3K4 methylation
at Hoxa9 loci in murine MLL-AF9 transformed cells and
reduce expression of Hoxa9 and Hoxa10 genes (81). Further-
more, this compound selectively inhibited growth of MLL
leukemia cells, induced apoptosis and differentiation of
these cells, albeit relatively high concentration of MM-401
(>10 lM) was required to demonstrate cellular activity
(81). Limited drug-like properties of peptidomimetics imply
that MM-401 would need to be re-designed to improve its
cellular activity and validate the effect of WDR5-MLL inhibi-
tors in in vivo models of MLL leukemia. Nevertheless, suc-
cessful development of both small molecule and
peptidomimetic inhibitors of the WDR5–MLL interaction
imply that this PPI represents a druggable target and inhibi-
tion of this interaction can modulate enzymatic activity of
MLL in hematologic malignancies.
The two examples of PPIs presented above demonstrate
that multiple interactions of MLL with its protein partners
(e.g. with menin or WDR5) could be disrupted by small
molecules for potential therapeutic applications. This is a
consequence of complexity of MLL and MLL fusion protein
complexes, with numerous domains playing a role in leuke-
mogenesis. Similar strategies have been proposed for target-
ing other multidomain proteins relevant in oncology,
including EZH2 HMT, which can be blocked by either inhi-
bition of the enzymatic activity (117, 118) or by disruption
of the EZH2-EED PPI (119).
Inhibitors targeting core binding factor-b
Development of small molecules targeting CBFb in acute
leukemias represents a successful example of disrupting PPIs
involving two globular domains (43). The two subunits of
the heterodimeric transcription factor CBF, CBFb, and
Runx1 (CBFa), are frequent targets of chromosomal trans-
locations found in acute leukemias (120, 121). The CBFb
is the target of a common chromosomal translocation,
inv(16), found in approximately 15% of AML cases (120),
which results in a fusion of the N-terminal 165 amino
acid fragment of CBFb to the smooth muscle myosin heavy
chain (SMMHC), leading to the expression of CBFb-
SMMHC fusion protein. CBFb-SMMHC causes dysregulation
of CBF function, and binding of Runx1 to CBFb is required
for dysregulation associated with the fusion protein (121,
122). Therefore, the PPI between CBFb and Runx1 repre-
sents a valuable target for inhibition as a potential thera-
peutic strategy for acute leukemias associated with CBF
rearrangements.
The interaction between CBFb and Runx1 has been char-
acterized in detail, including structural characterization of
the heterodimer (Figs 3 and 4C), its complex with DNA and
structures of individual monomers (123, 124). The Runx1-
CBFb represents a high affinity interaction (Kd = 54 nM)
(122), which involves two globular domains with a rela-
tively large and flat binding interface devoid of well-defined
pockets. The energetically important ‘hot spot’ residues have
been mapped on this PPI interface using alanine scanning
mutagenesis (125).
Efforts by Bushweller and colleagues (126) led to devel-
opment of small molecule inhibitors targeting CBFb to block
its interaction with the Runt domain. Initial compounds
were identified employing virtual screening based on the
NMR structure of CBFb, followed by experimental evalua-
tion of selected hits by NMR (43). These efforts resulted in
an aminothiazole class of compounds, which were validated
for binding to CBFb using NMR and demonstrated inhibi-
tion of the CBFb–Runx1 interaction as measured by
FRET-based and ELISA biochemical assays (43). Subsequent
chemistry optimization yielded analogs with improved
inhibitory activity, with the most potent compounds
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inhibiting the CBFb–Runx1 interaction with low micromolar
affinities (43) (Fig. 1D). Combination of NMR chemical shift
perturbations and computational approaches was used to
assess the binding mode of these compounds to CBFb (43).
Strikingly, these compounds bind to a novel allosteric site
on CBFb, offset from the CBFb-Runx1 interface (Figs 2 and
3). Because these compounds do not bind directly at the PPI
interface, their inhibitory effect occurs by means of an allo-
steric mechanism, likely via inducing conformational
changes, which are transmitted through the protein to the
residues at the CBFb-Runx1 interface.
The allosteric inhibitors of CBFb were shown to inhibit
the CBFb–Runx1 interaction in mammalian cells and inhib-
ited cell proliferation, induced apoptosis and differentiation
in the ME-1 human leukemia cell line expressing CBFb-
SMMHC (43). Finally, these compounds reduced Runx1
binding to DNA in cells, the interaction that is known to be
enhanced by CBFb. Overall, successful development of these
compounds and their effect in functional assays suggest that
CBFb-Runx1 inhibitors might have a potential therapeutic
value, although their further development is required to
identify compounds suitable for in vivo studies in animal
models of inv(16) leukemia. From the prospective of suc-
cessful targeting of PPIs, this case provides an important
example where allosteric inhibition might represent a feasi-
ble approach to target large and flat interfaces. More
recently, another inhibitor of the CBFb-SMMHC oncopro-
tein, AI-10-49, that disrupts its binding to Runx1 has been
described in the abstract form (126). This compound has
been reported to demonstrate both in vitro and in vivo efficacy
in inv(16) leukemia models, but detailed information about
this molecule is not available at this time.
Inhibitors of BET bromodomains
Small molecule inhibitors of the BET family of bromodo-
mains represent a highly successful example of PPI inhibi-
tors with strong therapeutic potential in hematologic
malignancies, particularly in AML and multiple myeloma
(84–86). The members of BET family of bromodomains,
which include Brd2, Brd3, Brd4, and Brdt, bind chromatin
to induce transcriptional activation (127, 128). The shRNA
screening for different chromatin regulators identified Brd4
as a target protein in AML (84).
Bromodomains are known chromatin binding modules
that recognize short peptides with acetylated lysine residues
(129). Structural studies of Brd4 complex with the acety-
lated histone derived peptide revealed that the acetylated
lysine binds to the relatively small and deep binding site on
Brd4 (130, 131) (Figs 4A and 5C). To date, multiple potent
inhibitors of the BET bromodomain family have been identi-
fied (129). Among these, JQ1, reported by Bradner and col-
leagues (128), is one of the most broadly used
bromodomain inhibitors (Fig. 1E). JQ1 binds to the first and
second bromodomain of Brd4 with Kd of 50 and 90 nM,
respectively, and inhibits the Brd4 interaction with the acet-
ylated histone H4-derived peptide with IC50 of 77 nM and
33 nM (128). The crystal structure of JQ1 in complex with
the Brd4 bromodomains revealed that JQ1 binds to the acet-
ylated lysine pocket and shows remarkable shape comple-
mentarity with this pocket (128) (Figs 2, 3, and 5D).
Furthermore, JQ1 mimics the interactions of the acetylated
lysine from the acH4 peptide with Brd4, including the
hydrogen bond with Asn140 (Fig. 5C and D). Pharmacologic
activity of JQ1 was evaluated in multiple AML cell lines and
AML patient samples, demonstrating strong anti-proliferative
effect, with the GI50 values better than 500 nM (84). In
addition, treatment with JQ1 resulted in myeloid differentia-
tion of MLL-AF9 leukemia cells (84). Importantly, JQ1
delayed progression of MLL leukemia in vivo and significantly
extended survival of MLL-AF9 leukemia mice. Furthermore,
activity of JQ1 was demonstrated in experimental models of
multiple myeloma in vivo, leading to a significant improve-
ment in survival (86).
Inhibitors of BET bromodomains have also been actively
developed by GlaxoSmithKline (85, 88, 132). Dawson et al.
(85) have tested whether displacement of BET proteins
from chromatin by a small molecule inhibitor may have a
therapeutic role in MLL leukemias. They used I-BET-151
dimethylisoxazole small molecule inhibitor (Fig. 1E), which
potently binds to and inhibits BET bromodomains (Kd of
20 nM and 100 nM for Brd3 and Brd4, respectively, and
IC50 < 0.7 lM for both proteins), and has optimized in vivo
pharmacokinetics (85). I-BET-151 showed potent and selec-
tive anti-proliferative effect in a panel of MLL leukemia
cells, with the GI50 values below 200 nM. In vivo studies
with I-BET151 in the MLL-AF4 and MLL-AF9 leukemia
models showed strongly reduced leukemia progression and
marked survival benefit. In the MLL primary patient sam-
ples, I-BET151 accelerated apoptosis and abrogated clono-
genic efficiency (85). Taken together, bromodomain
inhibitors demonstrate very promising activity in multiple
hematological malignancies, demonstrating a therapeutic
rationale for inhibiting this PPI. This exemplifies a great
potential in targeting PPIs, and several BET bromodomain
inhibitors are currently being evaluated in clinical trials
(Table 1).
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Small molecule inhibitors of BCL6
The BCL6 transcriptional repressor is the most frequent
oncogene involved in diffuse large B-cell lymphoma
(DLBCL) that is constitutively expressed in the majority of
patients with aggressive B-cell lymphomas (133). Delivery
of shRNA or peptide inhibitors of BCL6 kills DLBCL cells,
validating BCL6 as an attractive therapeutic target (133–
135). BCL6 is a member of the BTB/POZ family of tran-
scription factors, which recruits SMRT, N-CoR, and BCOR
corepressors (135). Several crystal structures of BCL6 BTB
domains bound with approximately 17 amino acid long
corepressor derived peptides were reported (136, 137).
Corepressors bind to the lateral groove formed at the inter-
face of the BTB domain dimer, and this binding occurs with
low micromolar affinities, which is relatively weak for PPIs
(136, 137).
Melnick and colleagues (87) applied computational meth-
ods to identify small molecules that bind to the BCL6 BTB
domain at the corepressor interaction site and inhibit this
PPI. The step-wise procedure, including virtual screening
searches of a library of approximately 1 million compounds
followed by experimental evaluation of 100 best scored hits,
was applied to identify initial lead compounds. One class of
small molecules, with the most potent compound 79-6
(Fig. 1F), was rigorously characterized, using both in vitro
and functional assays. Direct binding of 79-6 to the core-
pressor interaction site on BCL6 was validated using both
NMR spectroscopy and X-ray crystallography (87) (Fig. 2).
The indazoline ring anchors 79-6 in the binding groove on
BCL6 BTB, while the carboxyl tail becomes solvent exposed
(Figs 2 and 3). The NMR studies revealed relatively weak
binding affinity of 79-6 to BCL6 (Kd = 138 lM), further
supported by the fluorescence polarization data, demonstrat-
ing IC50 value of 212 lM for inhibition of the BCL6-SMRT
derived peptide interaction (87). Despite weak in vitro activ-
ity, 79-6 was shown to disrupt recruitment of N-CoR or
SMRT to BCL6 at the atr promoter in DLBCL cells, thus
affecting BCL6 transcriptional complexes, and altered expres-
sion of BCL6 target genes in DLBCL cell lines dependent on
BCL6. Interestingly, 79-6 was found to accumulate in cancer
cells and selectively kill BCL6-dependent DLBCL cells, with
the GI50 values at middle to high micromolar range (87).
The 79-6 compound showed favorable pharmacokinetic
profile (PK) and was tested in the xenograft models of
DLBCL, demonstrating significant inhibition of tumor
growth in the BCL6 dependent but no effect in the BCL6
independent xenografts. Taken together, the PPI between
BCL6 and corepressors represents a druggable target, and
targeting this PPI with small molecules might lead to an
effective anti-lymphoma strategy. The 79-6 compound
would require, however, further optimization to develop
compounds with optimized potency and improved drug-like
properties for more advanced preclinical and potentially
clinical evaluation.
Targeting protein–protein interactions: lessons learned
How to identify inhibitors of protein–protein
interactions?
Successful identification of the initial lead molecule that can
bind to the protein at the PPI interface represents a major
difficulty in the drug discovery campaign. In contrast to
enzymes, PPIs do not have a natural small molecule-like
ligand to substitute with a low molecular weight com-
pound. Nevertheless, the success in identifying small mole-
cule inhibitors of PPIs over the last decade highlights
different approaches to identify PPI modulators, which can
be classified as: (i) HTS of synthetic chemical libraries and
natural products; (ii) peptidomimetic approaches; (iii) bio-
physical and structural biology methods (NMR and X-ray
crystallography); and (iv) computational structure-based
drug design approaches (18). The first two approaches have
proven most successful in identification of PPI modulators
(18), possibly due to limited structural information available
for PPIs (16). Multiple reviews have described these
approaches in detail, providing specific examples (24, 138–
141). Here, we intend to highlight the methods used for
identification of PPI inhibitors targeting hematology-related
protein targets described above and refer to the key aspects
that are likely to guide discovery of new PPI modulators.
High throughput screening
High throughput screening of synthetic compounds and nat-
ural product libraries represents a traditional approach in
drug discovery, which has been successfully applied to the
discovery of lead compounds for enzymatic protein targets.
A growing number of examples demonstrate that HTS also
represents an effective approach for lead discovery of PPIs
(18, 78, 80, 142). This approach is particularly valuable
when structural information on the protein target is not
available, limiting application of structure-based design or
peptidomimetic approaches (18). The success of HTS in
identification of PPI inhibitors depends on multiple factors.
First, the ability of a particular PPI interface to be disrupted
by a small molecule (druggability), a property difficult to
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predict until such compounds are identified or detailed
structural analysis of the PPI interface is performed. Second,
small molecule compound libraries with a high degree of
molecular diversity and complexity are more desired to
block PPI interfaces than simply large size compound
libraries typically used for HTS (18). Finally, the choice of
biochemical assay for identification of PPI modulators,
which is in most cases a competitive binding assay, is
important for successful HTS, with fluorescence-based
screening assays playing a prevalent role (78, 80, 143–145).
While for the majority of PPIs more than one biochemical
assay can be developed, providing a choice for HTS, selec-
tion of the appropriate compound library represents a much
bigger limitation. HTS screening collections are typically
limited to commercial libraries, particularly in academic
drug discovery centers, which might not sample the appro-
priate chemical space for non-classical drug targets, such as
PPIs (58, 146, 147). The majority of current HTS libraries
represent a relatively small number of chemical scaffolds
and include molecules resembling existing drugs (146).
Inhibitors of PPIs, however, tend to be more complex (e.g.
higher molecular weight, high number of stereocenters,
macrocycles) than enzyme inhibitors (59). It has been pos-
tulated that diversity-oriented synthesis (DOS), which results
in compound libraries with increased scaffold complexity
(148, 149), and natural product libraries (58, 150, 151),
might be more suitable for identification of PPI modulators.
Despite these limitations, HTS has been successfully
applied to develop multiple PPI inhibitors, including our
own efforts to identify small molecule inhibitors of the
menin–MLL interaction (Fig. 1B), as described above (78,
80). The crystal structure of menin was not available when
HTS was performed, and therefore druggability of this PPI
interface could not be evaluated at that time. Biophysical
and biochemical characterization of the menin–MLL interac-
tion demonstrated that this is a protein–peptide type of
interface (109). We performed two independent HTS
screens, with total approximately 330 000 compounds
tested to identify menin-MLL inhibitors (78, 80, 152). The
striking result from both screens was a very low hit rate
(<0.08%) as compared to the typical range of 0.1–5% hit
rate in HTS for classical drug targets. Therefore, despite a
relatively large size of the screening collection and non-
stringent criteria applied for hit selection (IC50 < 200 lM),
only approximately 20 small molecule inhibitors of the
menin–MLL interaction were identified from HTS (78, 80).
Another example of successful HTS for PPIs in hematolog-
ic malignancies is identification of small molecule inhibitors
of the WDR5–MLL interaction (82). Biochemical screening
of a library of 16 000 diverse small molecules resulted in
only one compound with IC50 better than 60 lM (WDR5-
0101), demonstrating again a very low hit rate as compared
to the HTS with classical drug targets. Overall, these exam-
ples demonstrate that HTS can be successfully applied to
identify new PPI inhibitors, although a low number of hits
is expected. Results will vary, however, depending on the
nature of the PPI interface to block and libraries applied for
screening, as discussed above.
Peptidomimetic approaches
Peptides and peptidomimetics derived from PPI interfaces
have potential to serve as leads for development of PPI mod-
ulators (18). On the other hand, peptides and peptidomi-
metics might have drawbacks in drug discovery, due to
large molecular weight, conformational flexibility, limited
cellular permeability and proteolytic liability. Regardless of
these obstacles, a number of successful examples of peptide
derivatives and peptidomimetics have been reported (18,
153, 154). Inhibitors of the WDR5–MLL interaction repre-
sent a successful example of peptidemimetic approaches
applied for PPI relevant to acute leukemia, with both linear
and cyclic peptidomimetics developed using structure-based
design (81, 116) (Fig 1C), as described above in detail.
Despite a very potent in vitro activity (e.g. IC50 < 1 nM for
MI-401), modest cellular activity of these compounds
(>10 lM concentration required for activity in MLL leuke-
mia cells) demonstrates limited applicability and/or the
need for extensive optimization of peptidomimetics in drug
discovery projects.
Computational structure-based drug design
Computational approaches can assist different stages of drug
discovery process (18, 155). In the lead identification pro-
cess, virtual screening of large databases of compounds
based on the crystal or NMR structures of proteins have pro-
ven successful in reducing the size of compound collection
for experimental evaluation (18, 156). Relatively limited
success of computational approaches to lead identification
for PPIs often arises from limited structural information
available for PPI interfaces (16), flexibility of amino acids at
the interfaces, and the need for more accurate computational
methodologies. Despite these challenges, successful examples
of applying computational methods in lead identification for
PPIs have been reported (157, 158). One of the examples
supporting the utility of this approach is identification of
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small molecule inhibitors of the BCL6 protein identified by
virtual screening searches at the corepressor binding inter-
face (87). One class of compounds, represented by 79-6
(Fig. 1F), was validated for binding to BCL6 (Fig. 2), and
demonstrated activity in multiple in vitro and in vivo models
as described above. This example validates that computer-
aided drug design methods can be successfully used for lead
identification, albeit the activity of resulting hits might not
be very high, as demonstrated for BCL6 modulators
(IC50 > 100 lM) (87).
Biophysical methods in lead discovery
Biophysical and structural biology methods play a major role
in identifying molecules that bind to proteins via direct
measurement of the binding event. Different biophysical
methods have been applied to lead identification, including
NMR, isothermal titration calorimetry, and surface plasmid
resonance (SPR) (58, 159). NMR has been particularly valu-
able for detection of direct ligand binding to the protein as
it provides a possibility of mapping the ligand binding site
on the protein structure (58). This has been exemplified by
discovery of small molecule inhibitors of CBFb, which were
found to bind to the new allosteric site on the protein, as
assessed by mapping the NMR chemical shift perturbations
on the CBFb structure (43). Therefore, NMR is an extremely
valuable method not only for identification of new ligands
but also for mapping ligand binding sites on proteins and de
novo binding site identification in targets where allosteric site
is desired.
Fragment-based drug discovery
Fragment-based drug discovery (FBDD) is a relatively novel
approach used both in the pharmaceutical industry and aca-
demia for identification of new leads for previously intracta-
ble biological targets, including PPIs (22, 160, 161). FBDD
relies on identification of small molecular weight ligands
(<250 Da) that directly bind to the protein target by screen-
ing of relatively small compound libraries (up to few thou-
sand compounds). Fragment screening libraries sample
chemical space much more effectively than HTS libraries, as
hit rates typically observed in FBDD are 10–1000 times
higher than in conventional HTS screens (160, 162). The
fragment-based approach requires sensitive screening meth-
ods, such as NMR spectroscopy, SPR or thermal shift assay,
which allow identification of hits with weak affinities (high
micromolar to millimolar range) (163). Fragment hits are
subsequently extensively modified using medicinal chemistry
guided by structural biology to improve their potency and
pharmacological properties. FBDD has been validated as a
valuable drug discovery approach, and Vemurafenib, a small
molecule inhibitor of BRAF kinase, was the first approved
drug developed using this approach (164).
One of the most impressive stories in applying FBDD for
lead identification and optimization for PPIs is discovery of
Bcl-2 family inhibitors: ABT-737 and ABT-263 (Fig. 1). By
applying a ‘SAR by NMR’ strategy and screening few thou-
sand fragment-like compounds, Abbot identified very weak
(Kd > 300 lM) fragments that bind to the adjacent sites on
the Bcl-xL protein (165). Extensive medicinal chemistry
efforts supported by structural biology studies resulted in
ABT-737 and ABT-263, with Ki < 1 nM (166, 167), both
of which are currently in clinical trials (Table 1). More
recently, a fragment-based approach has been successfully
applied to lead identification for other PPIs, including Mcl-1
(168) and XIAP (169), which illustrates a strong potential
of FBDD to access new regions of chemical space required
for PPI inhibitors (170).
Is a crystal structure required for successful targeting of
protein–protein interactions?
Availability of structural information on a protein target is
invaluable even before a small molecule development pro-
gram is initiated, and it is even more critical at the stage of
lead identification and optimization. In an ideal situation,
the structure of a target protein alone and in complex with
the protein partner is desired to analyze the PPI interface
and account for potential conformational changes to address
protein dynamics at the interface. Detailed analysis of the
protein–protein interfaces facilitates a druggability assess-
ment to evaluate the potential for identification of small
molecule modulators of the PPI before screening is initiated.
Such studies are typically focused on analysis of the PPI
interface with respect to the size and presence of binding
pockets, which could possibly be occupied by small mole-
cules.
Availability of the crystal structure of a protein target is
also very beneficial during lead identification process, in par-
ticular when NMR is used as a screening method. The NMR
chemical shift perturbations observed upon ligand binding
can be mapped on the protein structure to validate direct
binding and identify ligand binding site, as demonstrated for
compounds targeting CBFb, where an unexpected allosteric
site was identified (43). Furthermore, hits identified using
other screening methods, e.g. HTS, can be validated by NMR
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for their direct binding to the target protein and their bind-
ing sites can be mapped onto the protein structure.
The crystal structures of the protein and ideally protein-
ligand complexes are essential for successful lead optimiza-
tion to efficiently direct medicinal chemistry efforts and
develop potent inhibitors with optimized drug-like proper-
ties. This requirement is even stronger in the context of
inhibitors targeting PPIs due to the lack of a natural small
molecule modulator that binds to the same site on the pro-
tein and could be mimicked by a small molecule inhibitor.
In our own studies, availability of the crystal structures for
the menin-inhibitor complexes enabled rapid optimization
of two classes of compounds, resulting in development of
compounds with nanomolar binding affinities (79, 80)
(Figs 1B and 5B). Similarly, for peptidomimetic inhibitors of
the WDR5–MLL interaction, extensive structure-based design
led to identification of very potent compounds (Ki < 1 nM)
(81, 116) (Fig. 1C). Other examples include inhibitors of
Bcl-2 family of proteins, ABT-737, and ABT-263 (166,
167) (Fig. 1A). It is important to point out that structural
data for protein-ligand complexes is critical for both optimi-
zation of potency and other drug-like properties (e.g. solu-
bility, PK profile) to recognize which sites on the ligand
molecule can be modified or substituted to modulate these
properties.
Which PPI interfaces are druggable?
Despite an increasing number of successful examples of PPI
inhibitors, there is an emerging picture that not all interac-
tions are amenable to disruption by small molecules. Analy-
sis of the successful examples for hematological targets
reveals that PPI most amenable to inhibition by small mole-
cules are protein–peptide type of interactions (Fig. 4A,B and
Fig. 6). This type of PPIs is typically characterized by a pres-
ence of well-defined concave binding sites at the PPI inter-
face and binding pockets with hydrophobic amino acids
(51, 52) (Fig. 5). Protein–peptide interactions are more
amenable to disruption by orthosteric inhibitors that bind to
the peptide binding site on the target protein (Fig. 6). Sig-
nificantly more challenging are PPIs involving globular
domains (Figs 4C and 6), and the most unapproachable are
PPIs composed of IDPs, which undergo coupled folding
upon binding to a protein partner (Fig. 6). Below we briefly
summarize features of different PPIs and provide successful
examples of their targeting by small molecule inhibitors.
Protein–peptide interactions: short peptide fragment
binds to a small and deep pocket
In this type of PPIs, short fragment of a protein partner
encompassing 6–8 amino acids binds to well-defined and
deep pocket located on a globular domain of a target pro-
tein. Examples include WDR5–MLL interaction (113) and
binding of acetylated histone peptides with BRD4 bromodo-
main (131) (Figs 3, 4A, and 5C). The contact surface formed
between peptide and binding site is relatively small in this
type of PPIs (Fig. 4A), and there is typically a key residue
within the peptide essential for high affinity interaction,
which inserts into a main binding pocket and mediates key
contacts with the protein partner. For example, an arginine
side chain of MLL plays such a critical role to form a stable
complex with WRD5 (113). Contacts with the backbone are
less extensive in such complexes, and it has been shown that
three amino acid long peptide derived from MLL is suffi-
cient to maintain a high affinity interaction with WDR5
(114). Bromodomains are also known to bind short
(approximately eight amino acid long) peptides and recog-
Fig. 6. Difficulty level in targeting protein–protein interactions (PPIs). Short peptide–domain complex is represented by Brd4-acH4 complex
(3UVW), long peptide–domain complex is represented by Bcl-2-BAX (2XA0), domain–domain complex is represented by CBFb-Runx1 (1H9D),
and complex of intrinsically disordered proteins is exemplified by AF9-AF4 (2LM0). Target proteins are shown in gray, and binding partners are
shown in different colors.
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nize one- or two-acetylated lysine residues (171) (Fig. 5C).
Capability to bind short peptides with a molecular weight of
600–800 Da suggests that such proteins could also bind
effectively small molecules (Fig. 6). Indeed, this type of PPIs
has been recognized as a particularly amenable target for
inhibition by small molecules (129). Domains that recog-
nize short peptides are abundant in chromatin binding pro-
teins (e.g. PWWP, MBT, tudor, PHD domains), strongly
suggesting a wealth of ‘druggable’ PPI interfaces in the
human genome.
Protein–peptide interactions: long peptide fragment
binds to the large site on globular domain
In this type of PPI a much longer peptide, typically encom-
passing 12–30 residues, binds to a globular domain. Within
examples described above this type of PPI is represented by
complexes: menin-MLL (109), Bcl-2 with BH3-domains
(172) and BCL6 with SMRT, BCOR corepressors (136, 137)
(Fig. 4B). In contrast to protein-short peptide interactions,
here the binding site is significantly larger and spreads over
a large part of a protein target, with multiple pockets
involved in the interactions. The interface is more complex
and buries a large surface area, typically exceeding 1000 A2
(Fig. 4B). The peptide motif in one of the binding partners
is unstructured when free in solution and undergoes folding
upon complex formation, frequently adapting a-helical or
b-strand conformation (45). PPIs involving larger surface
contacts are more prone to induce conformational changes
and form new pockets, as observed for the Bcl-2 family of
proteins (63). Development of small molecule inhibitors tar-
geting these interactions benefits from accurate mapping of
‘hot spot’ residues in order to identify key sites, which
could be occupied by a small molecule inhibitor (55)
(Fig. 6). Examples include menin-MLL inhibitor MI-2-2,
which closely mimics the key interactions of MLL with
menin (79) (Fig. 5A and B). High affinity synthetic inhibitors
targeting these interfaces are typically complex molecules
with elongated shape, capable of filling out multiple pock-
ets, and with a larger molecular weight than classical drugs
(61), as exemplified here by inhibitors targeting Bcl-2
(Figs 1A, 2, and 3).
Interfaces involving globular domains
Much less progress has been made in targeting interactions
involving globular domains. This type of PPIs is usually
characterized by a large and flat interface and lack of well-
defined pockets, making it very challenging to disrupt by
small molecules. The absence of pockets at PPI interfaces,
however, does not discriminate from identification of small
molecules as conformational dynamics of proteins may
induce formation of transient pockets at the interfaces (65).
Furthermore, cryptic pockets not present in the crystal struc-
tures of the apo protein may occur at allosteric sites (64).
In the context of hematology-related targets, the heterodi-
meric transcription factor CBFb-Runx1 (Figs 3 and 4) repre-
sents a successful example, where small molecule inhibitors
that bind to the allosteric site on CBFb were identified (43)
(Figs 1D, 3, and 4). These compounds bind, however, to a
relatively small pocket on CBFb (Figs 2 and 3) and have mod-
erate activity (IC50 ~ 1 lM). It remains to be shown
whether more potent inhibitors of this interaction can be
developed. Overall, the absence of deep pockets does not
exclude PPIs from initiating small molecule inhibitor devel-
opment, it does, however, indicate a greater challenge to
successfully identify such compounds (Fig. 6).
PPIs involving intrinsically disordered proteins
Intrinsically disordered proteins, which undergo coupled
folding upon binding to protein partner, belong to one of
the most challenging targets for drug discovery. Approxi-
mately 25% of mammalian proteins are predicted to be fully
disordered, and half of all proteins contain disordered
regions longer than 30 amino acids (173). IDPs participate
widely in the PPI network (49) and represent attractive tar-
gets for inhibitor development. However, it has been recog-
nized that designing drugs targeting IDPs remains a big
puzzle (174). These proteins represent a particular chal-
lenge, because there are no available computational methods
to predict binding of small molecule ligand to a disordered
protein (174).
A well-characterized example of PPIs involving IDPs in
hematological malignancies involves AF4 and AF9 proteins,
which are among the most common translocation partners
of MLL found in patients with acute leukemias (175). It has
been demonstrated that disruption of the AF4-AF9 PPI by a
short AF4-mimetic peptide in cells harboring MLL transloca-
tions results in cell death (176). Therefore, inhibition of the
AF4–AF9 interaction may represent an attractive therapeutic
target for MLL leukemias. Recent structural studies showed
that the AHD domain of AF9 and an interacting fragment of
AF4 are intrinsically disordered, when free in solution and
adapt a well-defined structure as an AF4-AF9 complex (48)
(Fig. 6). Such coupled folding results in burying an exten-
sive hydrophobic interface between the two proteins and
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leads to formation of a very stable complex. A small mole-
cule inhibitor capable of disrupting such a complex would
need to bind to the unstructured AHD domain of AF9, and
either form a stable complex with AF9 or stabilize the disor-
dered protein to prevent binding of AF4. Development of
small molecules targeting such PPIs represents a very diffi-
cult task (Fig. 6), and feasibility of identifying such com-
pounds would need to be demonstrated. One possibility to
block this PPI would be to develop peptidomimetics derived
from the AF4 structure.
When to move from lead identification to a drug
discovery program?
Validation of hits identified by screening compound libraries
for their direct binding to the target protein represents the
first step in selection of lead compounds for further optimi-
zation. This step is critical as many screening methods, par-
ticularly HTS, provide a large number of false positives
(143, 177, 178). Multiple biophysical methods are applied
for validation of direct binding of screening hits to proteins
(159, 179–181). Typically less than 30% of HTS hits identi-
fied for PPIs are confirmed for their direct binding to the
target protein. Once validated, the most promising lead
compounds are selected for medicinal chemistry optimiza-
tion, based on their activity, chemical tractability and physi-
cochemical properties. Structural information on the
protein-ligand complex is critical in lead optimization (see
above).
Validated screening hits targeting PPIs typically have in vi-
tro activity at the micromolar range and, therefore, substan-
tial optimization of these compounds is required to initiate
cell-based studies. For example, for the menin-MLL inhibi-
tors at least 50-fold improvement in the in vitro activity of
the HTS hits was required to achieve IC50 ~ 50 nM, before
these compounds demonstrated relatively potent activity and
selectivity in cell-based assays (79, 80). In addition to in vi-
tro potency, optimization of physicochemical properties,
including solubility and cellular permeability, are equally
important. For example, very potent (Ki < 1 nM) pepti-
domimetics were developed for the WDR5–MLL1 interac-
tion (81, 116), however, their effect in MLL leukemia cells
is rather modest likely due to limited cellular permeability.
This demonstrates that very potent in vitro inhibition of PPIs
by small molecules does not guarantee a strong effect in
biological experiments, and optimization of drug-like prop-
erties is typically required before compounds demonstrate
activity in cells and animal models of diseases.
The question to answer in a lead optimization process is
when to move from lead identification to a drug discovery
program focused on development of compounds with in vivo
efficacy and eventually a clinical candidate? Comprehensive
validation of the mechanism of action of a new PPI inhibi-
tor, both in vitro and in relevant cellular assays, are required
to consider investing substantial resources into further opti-
mization of a particular lead class within a drug discovery
project. If supported, the next step typically includes efficacy
evaluation of compounds in the appropriate animal models.
To reach this stage, potent cellular activity (GI50 at submi-
cromolar level or better), favorable pharmacokinetic profile
(PK) and low toxicity are required. In many drug discovery
programs extensive medicinal chemistry efforts are necessary
to develop compounds with the desired drug-like properties
and satisfactory in vivo effect in animal models, as exempli-
fied for PPI inhibitors of Bcl-2 family of proteins (166,
167), BET bromodomains (88) and in our own efforts with
optimization of the menin-MLL inhibitors (not shown). An
exception is the Bcl-6 inhibitor, 79-6, which demonstrates
significant in vivo efficacy in the Bcl-6 dependent xenografts
of lymphoma, despite relatively weak cellular activity (GI50
at middle to high micromolar level), likely due to accumu-
lation of the compound in the tumor samples (87).
How far we can pursue drug discovery programs in
academia?
Over the past decade the contribution of academic research
to drug discovery has been significantly increased, as
recently reviewed in a number of articles (182–185). The
role of academic laboratories is particularly valuable in drug
discovery for rare and neglected diseases (186), which
receive less industrial attention. Furthermore, novel and
more risky drug targets not yet validated clinically, such as
the majority of PPIs, are also primarily explored in academic
laboratories. Academic researchers can contribute to differ-
ent stages of the preclinical drug discovery process (184,
186). Historically, academic laboratories have a great record
of success with target identification and validation. More
recently, substantial investment has been provided to aca-
demic institutions to set-up early stage drug discovery plat-
forms, such as HTS screening capabilities, both at NIH
(MLPCN) (https://mli.nih.gov/mli/mlpcn/) and at individ-
ual academic institutions (152). Furthermore, some aca-
demic centers have created core facilities for medicinal
chemistry, PK, and animal studies, all of which are critical
to successfully pursue drug discovery projects (183). Our
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own efforts with developing PPI inhibitors strongly support
the model of utilizing different core facilities available to
academic laboratories. Collaboration with the HTS screening
center and other drug discovery oriented core facilities avail-
able at the University of Michigan (152) was essential to
the successful development of menin-MLL inhibitors
(78–80).
Academic drug discovery research is, however, limited by
multiple factors. First, such projects require substantial
resources, especially at more advanced preclinical stages
where extensive animal studies and outsourced assays to
assess drug-like properties of compounds need to be con-
ducted. Classical research grant funding might not be suffi-
cient to efficiently pursue such studies to identify candidates
for advanced preclinical or clinical work. This limitation can
sometimes be overcome by additional drug discovery sup-
porting mechanisms available from the National Institutes of
Health (NIH), such as the NEXT (NCI Experimental Thera-
peutics Program) program (http://next.cancer.gov/), which
allows Investigators to advance potential therapies by access-
ing resources within NIH to facilitate drug development. In
the context of hematologic malignancies, the role of the
Leukemia and Lymphoma Society Therapy Acceleration Pro-
gram (www.lls.org) is invaluable to help with advancing
very promising drug discovery projects to clinical stages.
Another limitation in academic drug discovery projects
might be a limited access to specific drug discovery
resources, such as appropriate screening libraries for HTS
(discussed above). Again, the support from NIH, such as
access to the NIH MLPCN screening collection of over
300 000 compounds, represents an alternative to partly
address this problem. Indeed, by screening the NIH com-
pound collection we identified several novel chemical scaf-
folds as menin-MLL inhibitors (80). An additional limitation
in academic drug discovery is the need for very extensive
medicinal chemistry optimization of lead compounds to
optimize their drug-like properties and develop compounds
appropriate for efficacy studies in animals, with optimized
PK and ADME (Adsorption, Distribution, Metabolism, Excre-
tion) properties. To overcome these limitations and also to
successfully move toward more advanced preclinical stages
and eventually to the clinic, a partnership with pharmaceuti-
cal or biotech companies might be required.
Taken together, drug discovery projects can be success-
fully pursued in academic institutions, especially at the ear-
lier stages of preclinical development. For novel and more
challenging drug targets, such as the majority of PPIs in
oncology and hematology, comprehensive target validation
studies and in vivo proof-of-principle studies might be
required to attract industrial attention. Despite all difficulties
and limitations, we expect that academic drug discovery
research will play a very significant role, particularly in the
area of challenging new targets like PPIs.
What has changed in targeting PPIs?
Drug-like small molecule inhibitors of PPIs have been, in
general, considered very difficult to develop (23–25, 187).
Until recently, the potential of successful development of
such compounds was viewed with much skepticism. It
was believed that targeting PPI interfaces is too difficult
due to: (i) unfavorable topology of PPI interfaces, (ii) lack
of natural small molecules that bind to PPI interfaces, (iii)
lack of appropriate screening libraries (23, 187, 188).
However, the last several years have resulted in multiple
examples of small molecule inhibitors targeting new PPIs
(18, 22, 25, 156, 189). Importantly, several PPI inhibitors
have already reached clinical trial stages (22) (Table 1),
revealing that drug-like properties of these compounds can
be optimized despite the larger molecular weight and
more hydrophobic nature of these compounds as com-
pared to existing drugs. The progress in targeting PPIs
with small molecules is in part associated with better
understanding of ‘druggable’ PPI interfaces (see above).
Structural studies on PPI interfaces and cocrystal structures
of small molecule inhibitors in complex with target pro-
teins provided important guidelines, which PPIs are more
tractable for inhibition (Fig. 6). Repertoire of methods
used in drug discovery has been expanded by fragment-
based approach, which is particularly suitable for targeting
more difficult PPIs, as exemplified by development of
inhibitors of Bcl-2 family that are currently evaluated in
clinical trials (161). Besides, discovery of new druggable
classes of PPIs with a strong link to human diseases, such
as bromodomains, increases optimism about feasibility of
successful targeting of PPIs.
The overall conclusion from the studies performed within
the last 10–15 years in the field of PPI inhibition proved
that they can be blocked by small molecules, but are in gen-
eral more challenging than classical drug targets. Moreover,
not all PPIs are equal in this regard, as some are more trac-
table for inhibition by small molecules than others, with
inhibitors already in clinical trials (Table 1) or at advanced
preclinical stages (see above), providing a big opportunity
for future therapies. Nevertheless, successful development of
these compounds provides a substantial promise to hematol-
ogy patients and strong foundation to the researchers to
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continue development of PPI inhibitors. Detailed character-
ization and analysis of the interfaces at the molecular level is
crucial for selection of PPIs with the highest likelihood of
success for a new drug discovery program.
PPI inhibition: questions to answer
Despite recent progress in targeting PPIs, multiple questions
still remain to be answered. One of the critical questions is
whether PPI inhibitors can be advanced to achieve the level
of potency and selectivity, as well as other properties, includ-
ing cellular permeability and pharmacokinetic profile,
required for drugs. Some of the examples discussed above,
including Brd4, Bcl-2 family, and MDM2 inhibitors that have
reached the stage of clinical trials (Table 1), suggest that this
goal can be achieved. Other PPI inhibitors described here
(Fig. 1) are still at the stage of preclinical optimization, and
more efforts are required to address this question. The suc-
cess in advancing PPI inhibitors to drug molecules might
depend on both druggability of a particular PPI interface and
the chemical nature of compounds selected for optimization.
In general, small molecules are more amenable to optimiza-
tion of drug-like properties than peptides and peptidomimet-
ics, although the success depends on the chemical scaffold.
Another important question is what chemical space
corresponds to the effective blocking of PPIs? With the
increasing number of successful examples of PPI inhibitors,
especially those that have entered the clinic, it became evi-
dent that the molecular weight of PPI inhibitors is much lar-
ger (Mw > 500 Da) and they are more hydrophobic
(clogP > 4.0) than classical drugs (20), and therefore most
of them do not fit into the Lipinski’s ‘Rule-of-Five’ for
orally bioavailable drugs (190). Despite these differences,
successful optimization of these compounds to a clinically
acceptable profile was possible, demonstrating that new
rules might apply to PPI inhibitors with regard to their size
and physicochemical properties (20).
An additional question is whether inhibiting PPIs would
present a therapeutically useful potential and advantage over
classical drugs such as enzyme inhibitors. Promising preclin-
ical and early stage clinical data for compounds described
above, as well as clinical use of PPI inhibitors blocking
tubulin polymerization and the mTOR–FKBP12 interaction
(22), demonstrate that PPI inhibition can be therapeutically
beneficial. However, more clinical examples are required to
prove the therapeutic value of this approach, and the next
several years should provide such data for PPI inhibitors
currently in clinical trials (22).
The remaining question associated with targeting PPIs is
how to predict druggability of new protein–protein inter-
faces. Structural analysis of PPI interfaces can be particularly
helpful in druggability assessment (20, 25), as discussed
above in details, for development of orthosteric inhibitors.
It is also important to consider allosteric inhibition as an
alternative solution to overcome limitations of PPI interfaces
less predisposed to inhibition by small molecules.
Future of targeting PPIs for therapeutic applications
The increasing number of new PPI inhibitors being discov-
ered and success with advancing these compounds into the
clinic, implies that small molecule inhibitors of PPIs will
remain an attractive opportunity for developing new thera-
peutics in the next decade. Given the size of the human in-
teractome with the estimated number of PPIs reaching
approximately 650 000 (27), many of which are already
known to play a critical role in human diseases (13), it
becomes evident that many new PPIs will be explored for
targeting by small molecules. Due to challenges and higher
risk associated with targeting new PPIs, academic research
will likely play an important role in drug discovery for pro-
tein–protein interfaces. In fact, the majority of PPI inhibitors
discussed here were developed in academia. Once the criti-
cal proof of concept regarding druggability of a new PPI
and its essential role in the diseases progression are estab-
lished, attention from pharmaceutical industry will become
more apparent.
The growing number of successful examples of small mol-
ecule inhibitors of PPIs and an increase in structural data for
disease relevant PPIs will be very helpful in predicting, which
interfaces are more tractable for drug discovery. The success
in targeting PPIs within the next several years will also
depend on advancement in protein structure determination
and in silico screening methods. Broader application of bio-
physical methods to eliminate false positives from screening
assays (18, 179, 180, 191) will also have to grow. The
impact of more recent methodologies, such as fragment-
based screening applied to PPIs (168, 192, 193), is expected
to increase in the future with new libraries developed and
advancement in methods used for compound screening.
Design and preparation of appropriate compound libraries,
both for HTS and fragment-based screening, will also need to
be addressed based on the growing number of PPI inhibitors
to incorporate structural features present in these compounds.
In lead optimization for PPI targets, we will have to diverge
from the drug-like properties reflected by the ‘Rule-of-Five’
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(190), as already exemplified for inhibitors of the Bcl-2 fam-
ily (Table 1). The lead optimization process will likely be
fairly challenging to properly manage the pharmacokinetic
and ADME properties of larger compounds such as PPI inhibi-
tors for advancing them to the clinic (18). In summary,
despite challenges highlighted here, a combination of exist-
ing knowledge on successful PPI inhibitors and advances in
technologies applied to develop such compounds within the
past decade should facilitate discovery of new PPI modulators
for treatment of cancer and other diseases, including hemato-
logic malignancies. The fact that a number of small molecule
inhibitors of PPIs are currently in clinical trials provides hope
that more compounds will advance to this stage and might
eventually be approved for clinical use.
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